KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.

Following a $172 million public equity raise and conversion of its balance sheet from Bitcoin to Ethereum, Bit Digital has accumulated over 100K ETH to become one of the largest corporate treasury companies in the world led under Ethereum veteran Sam Tabar NEW YORK, July 7, 2025 /PRNewswire/ -- Bit Digital, Inc. (Nasdaq: BTBT) ("Bit Digital" or the "Company"), today announced the completion of its transition to an Ethereum treasury strategy. Following the close of its recent underwritten public offering, the Company raised approximately $172 million in gross proceeds and has deployed the net capital to purchase Ethereum ("ETH"). Additionally, ...

HOUSTON, July 7, 2025 /PRNewswire/ -- Nauticus Robotics, Inc. (NASDAQ: KITT), a leading innovator in autonomous subsea robotics and software solutions, today announced completion of its first quarter of the 2025 operating season. Nauticus is pleased to reaffirm its vision of combining with SeaTrepid to form a company capable of executing traditional remotely operated vehicle (ROV) work while simultaneously moving the industry into autonomy.